Biocon tests the waters with itolizumab in pandemic-ravaged India, and Celltrion announces early success with an agent for the South African variant.
Biocon Biologics, of Bengaluru, Karnataka, India, reported first-quarter revenues were up 26%, to $275.9 million, vs the comparable year-ago quarter, driven largely by the company's biosimilars, research services, and generics businesses.
Amid the resurgence of COVID-19 in India, the company has also seen an increase in demand for itolizumab (Alzumab), which has shown value in treating acute respiratory distress syndrome (ARDS) associated with COVID-19.
First-quarter biosimilar revenues were $89.6 million, up from $59.8 million a year earlier, representing a 53% improvement, the company said. Total net income was $34.7 million, up 95% from a year earlier.
During the just-ended quarter, Biocon received marketing authorizations from the European Commission for a bevacizumab biosimilar (Abevmy) and an insulin aspart biosimilar (Kixelle). Biocon also received approval from the World Health Organization (WHO) for its trastuzumab biosimilar (Ogivri) in the 150 mg and 420 mg formulations. A WHO approval is generally referred to as a “prequalification” and represents the WHO’s thumbs-up for product quality and manufacturing practices.
In a statement, Arun Chandavarkar, managing director of Biocon, said improved sales in the company’s biosimilars segment were characterized by revenue growth in emerging markets and market share gains for the company’s pegfilgrastim and trastuzumab biosimilars in developed markets. The company also noted revenue gains for its insulin glargine product (Semglee), which was introduced in the United States in August 2020 and for which the company is seeking biosimilar status.
Itolizumab, an IgG1 kappa anti-CD6 monoclonal antibody, received restricted emergency use approval in India in July 2020 for the treatment of cytokine release syndrome in patients with moderate-to-severe ARDS who were hospitalized with COVID-19. Originally launched in India for the treatment of chronic plaque psoriasis, the drug reduces T-cell infiltration at sites of inflammation without depleting T cells or B cells.
In its most recent earnings statement, Biocon said at least 6500 patients were treated with itolizumab in April 2021. In March, the company published results from a randomized phase 2 study of the safety and efficacy of itolizumab in patients with moderate-to-severe ARDS due to COVID-19.
Investigators found itolizumab improved the 1-month survival rate and lung function, with reduction in the need for ventilator or respiratory support. They concluded “Itolizumab is a promising, safe and effective immunomodulatory therapy for treatment of ARDS due to cytokine release in COVID-19 patients, with survival and recovery-benefit,” although further study was recommended and this was in accord with earlier published research that recommended a go-slow approach.
Celltrion Group
Celltrion Group, another biosimilar developer, reported promising preclinical results for the use of regdanvimab (CT-P59) in the treatment of 3 variants (K417N, E484K, and N501Y) of the South African COVID-19 mutation (B.1.351). The company said CT-P59 demonstrated a significant reduction in viral load of SARS-CoV-2. Enrollment of 1300 patients in a global phase 3 clinical trial to evaluate the efficacy and safety of CT-P59 has been completed.
“We are encouraged by the new data, which reinforces that Celltrion’s CT-P59 treatment could be effective against the South African variant and variant mutations,” said HoUng Kim, PhD, head of the Medical and Marketing Division at Celltrion Healthcare.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.